windtree therapeutics, inc. is a biotechnology company focused on developing novel kl4 surfactant therapies for respiratory diseases and other potential applications. windtree’s proprietary technology platform includes a synthetic, peptide-containing surfactant (kl4 surfactant ) that is structurally similar to human pulmonary surfactant — and novel drug-delivery technologies that are being developed to enable noninvasive administration of aerosolized kl4 surfactant. windtree is focused initially on improving the management of respiratory distress syndrome (rds) in premature infants as surfactant therapy has been shown to save lives in this condition. windtree believes that its proprietary technologies may make it possible, over time, to develop a pipeline of kl4 surfactant product candidates to address a variety of respiratory diseases for which there are few or no approved therapies and, in doing so, potentially deliver a lifetime of hope to patients and their families.
Company profile
Ticker
WINT
Exchange
Website
CEO
Craig E. Fraser
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ANSAN INC, ANSAN PHARMACEUTICALS INC, DISCOVERY LABORATORIES INC /DE/
SEC CIK
Corporate docs
IRS number
943171943
WINT stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
22 Apr 24
8-K
Material Modifications to Rights of Security Holders
19 Apr 24
S-3/A
Shelf registration (amended)
17 Apr 24
8-K
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
17 Apr 24
10-K
2023 FY
Annual report
16 Apr 24
8-K
Submission of Matters to a Vote of Security Holders
10 Apr 24
8-K
Entry into a Material Definitive Agreement
8 Apr 24
NT 10-K
Notice of late annual filing
2 Apr 24
DEF 14A
Definitive proxy
12 Mar 24
8-K
Departure of Directors or Certain Officers
16 Feb 24
Latest ownership filings
SC 13G/A
Lincoln Park Capital Fund, LLC
14 Feb 24
SC 13G/A
Lind Global Fund II LP
13 Feb 24
SC 13G
Flynn James E
1 Feb 24
SC 13G
Duvvuri Krishna
13 Nov 23
4
Craig Fraser
28 Sep 23
4
Craig Fraser
27 Sep 23
3
Jamie McAndrew
5 Sep 23
4
Daniel E. Geffken
29 Aug 23
4
Leslie J. Williams
25 Aug 23
4
Mark Strobeck
25 Aug 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.37 mm | 7.37 mm | 7.37 mm | 7.37 mm | 7.37 mm | 7.37 mm |
Cash burn (monthly) | 1.37 mm | 89.25 k | 1.56 mm | 2.22 mm | 1.28 mm | 1.10 mm |
Cash used (since last report) | 9.29 mm | 606.38 k | 10.62 mm | 15.12 mm | 8.73 mm | 7.50 mm |
Cash remaining | -1.92 mm | 6.76 mm | -3.26 mm | -7.75 mm | -1.36 mm | -136.88 k |
Runway (months of cash) | -1.4 | 75.7 | -2.1 | -3.5 | -1.1 | -0.1 |
Institutional ownership, Q3 2023
30.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 14 |
Opened positions | 4 |
Closed positions | 4 |
Increased positions | 3 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 201.80 mm |
Total shares | 2.75 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Center Laboratories | 1.54 mm | $2.19 mm |
Lind Global Fund II | 475.10 k | $1.01 mm |
Lincoln Park Capital Fund | 459.04 k | $1.09 mm |
Alyeska Investment | 136.52 k | $129.50 mm |
Huang James | 68.98 k | $0.00 |
Vanguard | 41.64 k | $39.50 mm |
Geode Capital Management | 14.20 k | $13.69 mm |
Tower Research Capital | 9.67 k | $9.18 mm |
UBS UBS Group AG - Registered Shares | 5.91 k | $5.61 mm |
WFC Wells Fargo & Co. | 30.00 | $28.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Sep 23 | Fraser Craig | Common Stock | Buy | Acquire P | No | No | 1.0199 | 2,500 | 2.55 k | 57,877 |
26 Sep 23 | Fraser Craig | Common Stock | Buy | Acquire P | No | No | 0.9 | 2,500 | 2.25 k | 55,377 |
23 Aug 23 | Fraser Craig | Common Stock | Grant | Acquire A | No | No | 0 | 45,867 | 0.00 | 52,877 |
23 Aug 23 | Fraser Craig | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.21 | 68,800 | 83.25 k | 68,800 |
23 Aug 23 | Eric Curtis | Common Stock | Grant | Acquire A | No | No | 0 | 14,667 | 0.00 | 15,920 |
23 Aug 23 | Eric Curtis | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.21 | 22,000 | 26.62 k | 22,000 |
News
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
18 Apr 24
Windtree Therapeutics Q4 2023 GAAP EPS $(0.95) Misses $(0.94) Estimate
17 Apr 24
Windtree Enter Asset Purchase Agreement With Varian Biopharmaceuticals To Acquire Certain Of Its Assets, Including A Proprietary Atypical Protein Kinase C Iota Inhibitor
8 Apr 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
2 Feb 24
Windtree Therapeutics Eliminates $15M Contingent Liability To Deerfield Management Company
26 Jan 24
Press releases
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
8 Apr 24
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
1 Feb 24
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
31 Jan 24
Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company
26 Jan 24
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
25 Jan 24